In Phase 3 clinical trials (REDEFINE 1 and REDEFINE 2), the cagrilintide and semaglutide combination was administered once weekly via subcutaneous injection, with dose escalation targeting 2.4 mg of each peptide weekly over a 68-week trial duration
Carcaterra and Caruso, 2021)
Honestly, its been wonderful
A similar conversation is now emerging around obesity medicines: GLP-1 and dual agonists are being recognised internationally as evidence-based treatments for obesity with cardiometabolic benefit.[8] Indian insurers may progressively consider coverage when obesity is severe and linked with diabetes, heart disease, or sleep apnoea, rather than for cosmetic weight loss alone.[10] For families, this could mean negotiating group policies and reading the policy wording carefully to see if medically supervised GLP-1 therapy for obesity-with-complications is covered
Piollet, M
Warm environments can make dizziness worse Important: If your vertigo becomes severe, persistent, or gets worse over time, contact your healthcare provider immediately
